Can dulaglutide be titrated in a patient with an estimated glomerular filtration rate of 15 mL/min/1.73 m²?

Yes, dulaglutide can be titrated in patients with eGFR 15 mL/min/1.73 m²

Dulaglutide requires no dose adjustment at any level of kidney function, including severe CKD with eGFR 15 mL/min/1.73 m², and can be safely titrated to standard doses (0.75 mg or 1.5 mg weekly). 1

Key Evidence Supporting Use at eGFR 15

Guideline Recommendations

The most authoritative guidance comes from multiple high-quality sources:

• KDIGO 2020/2022 guidelines explicitly state dulaglutide can be used with eGFR >15 mL/min/1.73 m² with no dosage adjustment 2, 3

• ADA/KDIGO 2022 consensus confirms no dose adjustment required for dulaglutide across all CKD stages, including severe disease 4

• Endocrine Reviews 2020 comprehensive guideline tables show dulaglutide undergoes proteolytic catabolism (not renal clearance), requiring no dose adjustment even in ESKD/dialysis 1

FDA Label Information

The FDA-approved prescribing information confirms dulaglutide has been studied in patients with eGFR as low as 15 mL/min/1.73 m² 5:

• The AWARD-7 trial specifically enrolled patients with moderate-to-severe CKD (stages 3-4), with 30% having eGFR <30 mL/min/1.73 m²
• No dose adjustments were required based on renal function
• The label instructs to "monitor eGFR in patients with CKD reporting severe adverse gastrointestinal reactions" but does not restrict use

Mechanism Supporting Safety

Dulaglutide is metabolized via proteolytic catabolism, not renal excretion, which fundamentally distinguishes it from renally-cleared GLP-1 RAs like exenatide 1. This pharmacokinetic profile allows safe use across the full spectrum of CKD without accumulation risk.

Clinical Trial Evidence at Low eGFR

The AWARD-7 trial 6 and REWIND cardiovascular outcomes trial 5 both included patients with severe CKD:

• AWARD-7: Mean baseline eGFR was 38 mL/min/1.73 m², with 30% <30 mL/min/1.73 m²
• Dulaglutide 0.75 mg and 1.5 mg both demonstrated non-inferior glycemic control compared to insulin glargine
• Importantly, eGFR was higher at 52 weeks with dulaglutide (34.0 and 33.8 mL/min/1.73 m²) versus insulin glargine (31.3 mL/min/1.73 m²), suggesting potential renoprotective effects 6

Real-world studies confirm these findings 7, 8, 9, 10:

• Dulaglutide reduced eGFR decline rate from -2.41 to -0.76 mL/min/1.73 m²/year in CKD patients 8
• Benefits were particularly pronounced in patients with eGFR <60 mL/min/1.73 m² 8, 9

Practical Titration Approach

Start with dulaglutide 0.75 mg weekly, then titrate to 1.5 mg weekly after 4 weeks if tolerated and additional glycemic control needed 2:

1. Initiation: Begin 0.75 mg subcutaneously once weekly
2. Monitoring: Check for gastrointestinal symptoms (nausea, vomiting, diarrhea occur in 15-20% of CKD patients) 4
3. Titration: After 4 weeks, increase to 1.5 mg weekly if:
   • GI symptoms are tolerable or resolved
   • Additional HbA1c reduction needed
   • No severe adverse reactions
4. eGFR monitoring: Expect potential transient eGFR changes; monitor but do not discontinue unless severe GI symptoms cause volume depletion 1

Critical Safety Considerations

Monitor for GI-Related Volume Depletion

The primary concern at eGFR 15 is severe gastrointestinal adverse reactions causing volume depletion and acute kidney injury 1. If severe nausea, vomiting, or diarrhea occur:

• Ensure adequate hydration
• Monitor eGFR closely
• Consider temporary dose reduction or holding medication until symptoms resolve

Hypoglycemia Risk

When used with insulin or sulfonylureas, reduce doses of these agents to prevent hypoglycemia 4. Dulaglutide alone carries minimal hypoglycemia risk.

Contraindications

The only GLP-1 RA to avoid at eGFR 15 is lixisenatide (avoid if eGFR <15) 1. Exenatide is contraindicated at eGFR <30 1.

Cardiovascular and Renal Benefits Preserved

The cardiovascular and renal protective effects of dulaglutide are maintained even at low eGFR 4:

• REWIND trial included patients with eGFR as low as 15 mL/min/1.73 m²
• Reduced MACE by 12% (HR 0.88,95% CI 0.79-0.99)
• Benefits were particularly pronounced in patients with eGFR <60 mL/min/1.73 m² 4

Bottom Line Algorithm

For patients with T2D and eGFR 15 mL/min/1.73 m²:

1. ✓ Initiate dulaglutide 0.75 mg weekly (no dose adjustment needed)
2. ✓ Titrate to 1.5 mg weekly after 4 weeks if tolerated and needed for glycemic control
3. ✓ Continue even if eGFR declines further unless dialysis initiated or intolerable side effects 2, 3
4. ✓ Monitor for GI symptoms and volume status more closely than in patients with normal renal function
5. ✓ Reduce insulin/sulfonylurea doses if used concomitantly to prevent hypoglycemia

This approach prioritizes both glycemic control and the proven cardiovascular/renal benefits of dulaglutide while maintaining safety in advanced CKD.